Divergent Risks of Hematologic Malignancies Associated with GLP-1 Receptor Agonists and SGLT2 Inhibitors: Preliminary Findings from a Pilot Network Meta-Analysis
Our preliminary findings reveal distinct and agent-specific effects of GLP-1 receptor agonists on hematologic malignancy risk. While dulaglutide may elevate the risk, tirzepatide appears protective, particularly against lymphoma. These results call for further long-term mechanistic studies to clarify causality and underlying pathways.
Authors
- Brendon Stubbs (ORCID: https://orcid.org/0000-0001-7387-3791)
- Bing‐Yan Zeng
- Wei‐Te Lei (ORCID: https://orcid.org/0000-0003-1677-8901)
- Kuan‐Pin Su (ORCID: https://orcid.org/0000-0002-4501-2502)
- Tien‐Yu Chen (ORCID: https://orcid.org/0000-0001-8462-1311)
- Chih‐Sung Liang (ORCID: https://orcid.org/0000-0003-1138-5586)
- Ping‐Tao Tseng (ORCID: https://orcid.org/0000-0001-5761-7800)
- Pao‐Yen Lin (ORCID: https://orcid.org/0000-0002-1394-4567)
- Chih‐Wei Hsu (ORCID: https://orcid.org/0000-0002-8650-4060)
- Mein‐Woei Suen (ORCID: https://orcid.org/0000-0002-3991-0322)
- Yen-Wen Chen
- Bing‐Syuan Zeng
- Chao-Ming Hung
- Jiann-Jy Chen
Institutions
- University of Vienna (AT)
- National Sun Yat-sen University (TW)
- Asia University (TW)
- Chang Gung University (TW)
- King's College London (GB)
- China Medical University (TW)
- Mackay Memorial Hospital (TW)
- An-Nan Hospital (TW)
- Kaohsiung Chang Gung Memorial Hospital (TW)
- Austrian Institute for Sports Medicine (AT)
- China Medical University Hospital (TW)
- National Defense Medical Center (TW)
- I-Shou University (TW)
Publication Details
- Journal
- Biomolecules
- Published
- 2025-11-19
- DOI
- https://doi.org/10.3390/biom15111622
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59